Bio-Rad Laboratories, Inc. (BIO.B)

Bio-Rad Laboratories Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	369.3	488.1	403.8	434.22	470.78	662.21
Short-Term Investments	1,005	1,176	1,203	1,356	399.14	328.91
Cash & Short-Term Investments	1,374	1,665	1,607	1,791	869.92	991.12
Cash Growth	-14.99%	3.57%	-10.25%	105.84%	-12.23%	-11.08%
Accounts Receivable	469.9	452.5	489	494.65	423.54	419.42
Other Receivables	8.1	13.1	11.9	11.6	2.2	1.4
Receivables	478	465.6	500.9	506.25	425.74	420.82
Inventory	798.8	760	780.5	719.32	572.24	622.25
Prepaid Expenses	149.6	122.6	140	124.18	109.14	90.62
Restricted Cash	2	1.4	0.2	0.01	0.01	3.99
Other Current Assets	8.9	16.2	19.6	17.55	13.44	11.03
Total Current Assets	2,811	3,030	3,048	3,158	1,990	2,140
Property, Plant & Equipment	740.1	688.6	723.7	679.56	716.44	693.51
Long-Term Investments	5,575	4,838	7,697	8,830	14,386	9,560
Goodwill	581.6	410.5	413.6	406.49	347.34	291.92
Other Intangible Assets	396.9	293.6	320.5	332.15	253.94	199.5
Other Long-Term Assets	109.2	103.5	96.4	95.8	105.49	87.82
Total Assets	10,214	9,364	12,299	13,502	17,799	12,973
Accounts Payable	139.3	122.3	144.6	135.04	141.94	139.45
Accrued Expenses	157.8	124.2	139.9	194.79	312.97	256.93
Current Portion of Long-Term Debt	0.8	0.8	-	-	-	1.3
Current Portion of Leases	39.8	42.1	40.9	36.8	36.92	37.01
Current Income Taxes Payable	36.2	31.2	35.8	32.43	10.32	23.28
Current Unearned Revenue	-	-	-	-	50.85	42.47
Other Current Liabilities	175	147.2	161.6	169.65	127.94	131.1
Total Current Liabilities	548.9	467.8	522.8	568.71	680.94	631.54
Long-Term Debt	1,192	1,191	1,190	1,188	0	1.26
Long-Term Leases	173.7	140.6	175.1	163.73	186.45	186.13
Long-Term Deferred Tax Liabilities	961	818	1,476	1,770	3,065	2,077
Other Long-Term Liabilities	209.6	120.3	135.5	150.61	108.39	102.17
Total Liabilities	3,085	2,795	3,558	3,886	4,114	3,093
Common Stock	-	-	-	0	0	0
Additional Paid-In Capital	484.6	463.2	449.1	447.45	441.73	429.38
Retained Earnings	7,798	7,416	9,261	9,898	13,525	9,268
Treasury Stock	-1,000	-772.1	-632.5	-263.59	-106.29	-99.91
Comprehensive Income & Other	-154.1	-538.2	-336	-466.82	-175.55	282.46
Shareholders' Equity	7,129	6,569	8,741	9,615	13,685	9,880
Total Liabilities & Equity	10,214	9,364	12,299	13,502	17,799	12,973
Total Debt	1,407	1,375	1,406	1,388	223.38	225.69
Net Cash (Debt)	-32.7	289.8	201.6	402.56	646.54	765.43
Net Cash Growth	-	43.75%	-49.92%	-37.74%	-15.53%	65.14%
Net Cash Per Share	-1.18	10.27	6.90	13.52	21.40	25.38
Filing Date Shares Outstanding	27.06	28.01	28.52	29.6	29.93	29.84
Total Common Shares Outstanding	27.06	28.01	28.52	29.6	29.93	29.84
Working Capital	2,262	2,563	2,526	2,589	1,310	1,508
Book Value Per Share	263.42	234.52	306.51	324.89	457.20	331.05
Tangible Book Value	6,150	5,865	8,007	8,877	13,084	9,389
Tangible Book Value Per Share	227.26	209.39	280.77	299.93	437.12	314.59
Land	-	27.8	28.4	27.8	27.94	25.74
Buildings	-	426.3	419.8	393.6	385.8	363.05
Machinery	-	1,183	1,148	1,087	1,100	1,064

Updated May 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q